

NDA 50-760

SmithKline Beecham
Attention: Dennen R. Stewart, Ph.D.
Regulatory Associate, U.S. Regulatory Affairs
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

Dear Dr. Stewart:

Please refer to your new drug application (NDA) dated April 15, 1998, received April 16, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Amoxil[®] (amoxicillin) for Oral Suspension. We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated June 19, 1998; January 13, 1999, February 12, 1999, March 23, 1999, and April 6, 1999.

This new drug application provides for the use of Amoxil (amoxicillin) for oral suspension 200 mg/5 mL and 400 mg/ 5mL in divided doses q12h.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling submitted on April 6, 1999. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 50-760." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

As of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We are waiving the pediatric study requirement for this application.

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Mr. Steve Trostle, Project Manager, at 301-827-2125.

Sincerely,

Janice Soreth, M.D.
Acting Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research